Legal & General Group PLC Neurocrine Biosciences Inc Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Legal & General Group PLC holds 574,162 shares of NBIX stock, worth $72.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

574,162

Previous 540,106 6.31%

Holding current value

$72.1 Million

Previous $74.5 Million 6.11%

% of portfolio

0.02%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $4.46 Million - $4.88 Million	34,056 Added 6.31%	574,162 $79 Million
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $4.8 Million - $5.29 Million	-36,782 Reduced 6.38%	540,106 $74.5 Million
Q4 2023 Feb 15, 2024	BUY	$106.07 - $132.76 $13.7 Million - $17.1 Million	128,740 Added 28.73%	576,888 $76 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $901,087 - $1.12 Million	-9,584 Reduced 2.09%	448,148 $50.4 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $3.24 Million - $3.79 Million	-36,186 Reduced 7.33%	457,732 $43.2 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $253,720 - $331,661	2,696 Added 0.55%	493,918 $50 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $620,683 - $738,980	-5,816 Reduced 1.17%	491,222 $58.7 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $890,114 - $1.04 Million	-9,672 Reduced 1.91%	497,038 $52.8 Million
Q2 2022 Aug 22, 2022	BUY	$75.79 - $100.07 $2.52 Million - $3.33 Million	33,279 Added 7.03%	506,710 $49.4 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $1.9 Million - $2.49 Million	26,254 Added 5.87%	473,431 $44.4 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $234,489 - $312,711	-2,944 Reduced 0.65%	447,177 $38.1 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $140,042 - $160,923	1,625 Added 0.36%	450,121 $43.2 Million
Q2 2021 Aug 12, 2021	BUY	$89.43 - $102.27 $3.84 Million - $4.39 Million	42,915 Added 10.58%	448,496 $43.6 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $5.86 Million - $7.99 Million	66,890 Added 19.75%	405,581 $39.4 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $2.56 Million - $3.19 Million	-29,488 Reduced 8.01%	338,691 $32.5 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $894,864 - $1.26 Million	-9,306 Reduced 2.47%	368,179 $35.4 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $8.08 Million - $12.4 Million	94,980 Added 33.62%	377,485 $46.1 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $1.59 Million - $2.41 Million	21,196 Added 8.11%	282,505 $24.5 Million
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $17.1 Million - $23.4 Million	197,544 Added 309.8%	261,309 $28.1 Million
Q3 2019 Nov 13, 2019	BUY	$83.82 - $101.5 $961,163 - $1.16 Million	11,467 Added 21.93%	63,765 $5.75 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $51,868 - $65,531	718 Added 1.39%	52,298 $4.42 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $622,888 - $822,580	-8,987 Reduced 14.84%	51,580 $4.54 Million
Q4 2018 Feb 15, 2019	SELL	$68.32 - $124.36 $314,135 - $571,807	-4,598 Reduced 7.06%	60,567 $4.33 Million
Q3 2018 Nov 20, 2018	BUY	$98.88 - $125.85 $2.51 Million - $3.19 Million	25,365 Added 63.73%	65,165 $8.01 Million
Q2 2018 Aug 10, 2018	SELL	$75.3 - $105.99 $377,328 - $531,115	-5,011 Reduced 11.18%	39,800 $3.91 Million
Q1 2018 May 17, 2018	SELL	$75.88 - $92.43 $42,568 - $51,853	-561 Reduced 1.24%	44,811 $3.72 Million
Q4 2017 Feb 13, 2018	BUY	$58.53 - $77.59 $2.66 Million - $3.52 Million	45,372	45,372 $3.52 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Neurocrine Biosciences Inc Transaction History